Summary: NLS Pharmaceutics Ltd and Kadimastem Ltd have entered into a definitive merger agreement. The merged entity will focus on advancing NLS’s dual orexin agonist platform, which has applications in sleep disorders, and Kadimastem’s cell therapy programs targeting ALS and … [Read more...]
NLS Pharmaceutics Secures Patent for Dual Orexin Receptor Agonists
Summary: NLS Pharmaceutics Ltd announced the publication of a new patent application by Aexon Labs with the World Intellectual Property Organization, introducing a novel series of dual orexin receptor agonists. These compounds are designed to treat narcolepsy and … [Read more...]
NLS Secures Exclusive License for Dual Orexin Agonist Platform
Swiss biopharmaceutical enterprise NLS Pharmaceutics Ltd declared an exclusive worldwide license arrangement with Aexon Labs Inc, a US-centered biotech agency, to purchase global advancement and commercialization legal rights to Aexon’s twin orexin receptor agonists system. These … [Read more...]